Relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Gwan Gyu | - |
dc.contributor.author | Lee, Young Ho | - |
dc.date.accessioned | 2021-08-30T03:32:59Z | - |
dc.date.available | 2021-08-30T03:32:59Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/49706 | - |
dc.description.abstract | Aims: To assess the relative efficacy and tolerability of tanezumab (2.5. 5, and 10 mg) in osteoarthritis (OA) patients. Materials and methods: Six randomized controlled trials (RCTs) including 3,813 patients and examining the efficacy and tolerability of tanezumab (2.5, 5, 10 mg), naproxen (1,000 mg), and placebo, based on the number of withdrawals among osteoarthritis patients, were included in this Bayesian random-effects network meta-analysis, which combined direct and indirect evidence. Results: Taneztunab (5, 2.5. 10 mg) and 1,000 mg naproxen were more efficacious than placebo (odds ratio (OR): 0.34, 95% credible interval (CrI): 0.26 - 0.43; OR: 0.35, 95% CrI: 0.24 - 0.48; OR: 0.364, 95% CrI: 0.28 - 0.45; and OR: 0.44, 95% Crl: 0.32 - 0.61, respectively). The number of withdrawals due to lack of efficacy were lower in the tanezumab groups than in the naproxen group, and the difference was not significant. Ranking probability based on the cumulative ranking curve (SUCRA) indicated that 5 mg tanezumab had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy, followed by 2.5 mg tanezumab, 10 mg tanezumab, 1.000 mg naproxen, and placebo. Ranking probability based on SUCRA indicated that 2.5 mg tanezumab and placebo had the highest probability of being the most tolerable treatment, followed by 5 mg tanezumab, 1,000 mg naproxen, and 10 mg tanezumab. Conclusion: Tanezumab (5 mg) had the highest probability of being the best treatment based on the number of withdrawals due to lack of efficacy among the medications, while 2.5 mg tanezumab and placebo had the highest probability of being the most tolerable treatment. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | NERVE GROWTH-FACTOR | - |
dc.subject | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject | RHEUMATOID-ARTHRITIS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | KNEE PAIN | - |
dc.subject | HIP | - |
dc.subject | SAFETY | - |
dc.subject | TOXICITY | - |
dc.title | Relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.5414/CP203812 | - |
dc.identifier.scopusid | 2-s2.0-85101541756 | - |
dc.identifier.wosid | 000608823600007 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.59, no.2, pp.147 - 155 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 59 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 147 | - |
dc.citation.endPage | 155 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | NERVE GROWTH-FACTOR | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | KNEE PAIN | - |
dc.subject.keywordPlus | HIP | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordAuthor | tanezumab | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | tolerability | - |
dc.subject.keywordAuthor | osteoarthritis | - |
dc.subject.keywordAuthor | meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.